Immunotherapy plus radiation shows promise for tough prostate cancer

NCT ID NCT03543189

Ongoing Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding the immunotherapy drug nivolumab (Opdivo) to standard radiation and hormone therapy is safe and effective for men with a very aggressive form of prostate cancer (Gleason grade group 5). About 44 men will receive the drug combination. The goal is to see if it can delay cancer progression and improve outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab (Opdivo)
What this could lead to: If it works, this could offer a new treatment option for men with aggressive prostate cancer, potentially delaying cancer progression.
What could go wrong: This is an early-phase trial with only 44 participants, so results may not apply to everyone. The combination may cause side effects like immune reactions or toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER PROSTATE DISEASE

Contacts and locations

Locations

H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.